Mesa Laboratories, Inc. (MLAB)
After hours:
| Previous close | 91.70 |
| Open | 92.13 |
| Bid | 91.96 x 100 |
| Ask | 93.31 x 100 |
| Day's range | 90.78 - 93.80 |
| 52-week range | 82.86 - 145.46 |
| Volume | |
| Avg. volume | 38,295 |
| Market cap | 500.244M |
| Beta (5Y monthly) | 0.85 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -47.20 |
| Earnings date | 01 Aug 2024 - 05 Aug 2024 |
| Forward dividend & yield | 0.64 (0.70%) |
| Ex-dividend date | 31 May 2024 |
| 1y target est | 125.00 |
Simply Wall St.Mesa Laboratories Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags
Mesa Laboratories ( NASDAQ:MLAB ) Full Year 2024 Results Key Financial Results Revenue: US$216.2m (down 1.3% from FY...
GlobeNewswireMesa Labs Announces Fourth Quarter and Full Fiscal Year 2024 Results
LAKEWOOD, Colo., June 05, 2024 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB), a global leader in the design and manufacture of life science tools and critical quality control solutions, today announced results for its fourth fiscal quarter (“4Q24”) and fiscal year (“FY24”) ended March 31, 2024 (amounts in thousands). Fourth quarter FY24 compared to fourth quarter FY23: Revenues increased 6% and increased 10.2% vs 3Q24Non-GAAP core organic revenues1 decreased 3.5%Operating (loss) was
- GlobeNewswire
Mesa Laboratories, Inc. Revises Earnings Announcement date for Unaudited Fourth Quarter and Full Fiscal Year 2024 Results
LAKEWOOD, Colo., May 31, 2024 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (“Mesa”) (NASDAQ:MLAB) will not issue its 2024 financial results for the fourth quarter and the fiscal year ending March 31, 2024 today as previously communicated. The earnings announcement has been delayed as we work to finalize our year end audit which is focused on finalizing the calculations and technical accounting for previously-announced impairments of long-lived assets and goodwill related to our Clinical Genomics
